The arterial network was informed that according to Mobihealthnews news, the artificial intelligence startup Viz. Ai completed $21 million in Series A financing on July 18, US time. The leading investor was KPCB. Another participating institution included Alphabet's venture capital division GV (formerly Google Ventures).
Note: In 2015, Google was reorganized into Alphabet, and AI became the core of almost every department's strategy.
Viz. Ai's calendar year financing (source: Crunchbase)
Prior to this, Viz. Ai has raised about $10 million in funding, plus a total of $31 million in this round of financing. The company plans to apply the new funds it has raised to expand the new market and will use the range of diseases in which AI diagnoses disease technology.
According to the US Centers for Disease Control and Prevention, stroke is the fifth leading cause of death in the United States and the leading cause of severe disability in adults. About 795,000 people in the United States have a stroke every year, and a stroke occurs every 40 seconds. Every year, 140,000 people die from stroke, and those who survive a stroke often suffer from long-term disability due to morbidity and become disabled or disabled.
One of the fundamental problems of ineffective treatment of stroke is that the symptoms are difficult to diagnose and cannot be predicted before the onset of symptoms. Some patients may have clinical symptoms of transient ischemic attack such as dizziness, temporary limb numbness, and weakness.
The onset of stroke is often more acute, mostly in rest or sleep. Patients may have clinical symptoms such as orbital deviation, unfavorable language, and hemiplegia. If you do not receive timely treatment after a stroke, the chance of disability or death will increase significantly over time.
Detecting stroke with AI, has passed FDA certification
Viz. Ai was founded in 2016 and is headquartered in San Francisco, USA. The company is committed to using automated learning algorithms to analyze CT neuroimaging images to detect indicators related to stroke and provide clinical decision support. Viz. Ai's iconic products are the Viz LVO and Viz CTP platforms, both of which are FDA-approved and available in the US.
Viz LVO platform (Source: Viz.ai official website)
Viz LVO uses artificial intelligence to automatically detect large vessel occlusion (LVO) in suspected stroke patients, and notifications of suspected LVO are sent to neurologists and interventional physicians who can view the patient's CTA image on a mobile device. The time from the picture to the notification is less than 6 minutes. The stroke specialist can initiate a patient transfer to the intervention center by interacting with the existing emergency call function.
Viz CTP platform (Source: Viz.ai official website)
Another platform, Viz CTP, uses advanced processing techniques to automatically analyze CT perfusion neuroimaging images and generate parametric perfusion color maps. Extending the treatment window for mechanical thrombectomy from 6 hours to 24 hours according to the recent AHA / ASA guidelines has brought new cycles of appropriate treatment to stroke patients.
For selected patients within this treatment window, perfusion imaging is recommended to identify and select patients eligible for mechanical thrombectomy.
And the software is compatible with existing CT technology. No new or extra hardware. The processed output is automatically pushed to standard PACS and other DICOM compatible devices for viewing.
Use deep learning algorithms, Viz. Ai's software analyzes the CT scan to find stroke indicators and automatically alerts the stroke specialist. Diagnostic time can be reduced to a few seconds to gain valuable treatment time for stroke patients.
Advances in artificial intelligence and deep learning have made it possible to quickly and accurately analyze medical imaging. The ALADIN multicenter trial demonstrated the ability of Viz LVO to retrospectively and consistently and rapidly detect large vessel occlusion (LVO) in suspected stroke patients on 875 CTA images. The left ventricular flow detected by Viz LVO, extending from ICA-T to MCA-M1, has a sensitivity of 90% and a specificity of 86%. Therefore, Viz LVO is considered to be the most accurate LVO detection algorithm currently available in the United States.
For stroke patients, saving time is saving lives
Using the Viz LVO platform during the diagnosis process, timely intervention by stroke specialists may extend the treatment time for IV tPA and mechanical thrombectomy while ensuring that only appropriate patients are transferred.
Viz. Dr. Chris Mansi, co-founder of ai, believes that “every minute is important for stroke patients. Our goal is to fundamentally change health care, making it forward-looking rather than reactive. By integrating Viz, we Believe that the health care system can increase the chances of life-saving treatment and shorten the treatment time of its referral network."
Viz. Ai received a new 510(k) license in February for Viz. aiContact app. “A stroke can cause serious and irreversible damage to the patient. The software device can benefit patients by notifying the specialist earlier to reduce treatment time. Faster treatment may reduce the extent or progression of stroke,†FDA equipment and radiation Dr. Robert Ochs, deputy director of the Radiation Health Agency at the In Vitro Diagnostic and Radiation Health Office of the Health Center, said.
Viz. The AI ​​Contact application is a computer-aided classification software that uses artificial intelligence algorithms to analyze images of stroke-related metrics. Artificial intelligence algorithms are clinical decision support software that helps providers determine the most appropriate treatment for a patient's disease or condition. The FDA is currently developing a regulatory framework for these products, encouraging developers to create, adapt and extend the functionality of their software to help providers diagnose and treat diseases and conditions.
Viz. The AI ​​Contact application is designed to analyze CT images of the brain and send text notifications to neurovascular specialists when determining suspected large vessel obstructions. The algorithm will automatically notify the expert while the first-line provider is performing a standard review of the image, possibly involving the expert earlier than the usual standard of care, where the patient waits for the radiologist to examine the CT image and notify the neurovascular specialist. Notifications can be sent to mobile devices, such as smartphones or tablets, but experts still need to view images on clinical workstations.
Viz. The AI ​​Contact application is primarily intended for use by neurovascular specialists. This application is limited to the analysis of imaging data and should not be used to replace a complete patient assessment or rely solely on making or confirming a diagnosis.
In terms of investment institutions, GV has a long history of investment in life sciences, and recently invested in medical research machine learning startup Owkin, clinical trial technology company Science 37 and next-generation vaccine development startup SpyBiotech. Last year, Google announced a new artificial intelligence venture capital fund called Gradient Ventures, which invested in medical science for the first time this year and participated in BenchSci's $8 million financing to accelerate the discovery of biomedical research.
In addition, KPCB has invested in many artificial intelligence and healthcare startups for Viz. Ai this project, KPCB as its leader is also a natural chapter. KPCB partner Mamoon Hamid believes: “Many new medical technology solutions are difficult to appeal to hospitals because they often do not match existing procedures and require changes to the doctor's procedures and workflow. Doctors and their teams are pushing the Viz.ai platform because it doesn't break the original structure of the medical facility and fits well into the hospital's existing PACS system."
Fire Alarm By Bedroom,Bedroom Fire Alarm,Bedroom Fire Alarms,Bedroom Monoxide Alarm
Guangdong Isafenest Co.,Ltd. , https://www.isfenest.com